您当前的位置：

人参皂苷Rd

(Synonyms: 人参皂苷 Rd; Gypenoside VIII)

目录号: PC21349 纯度: 分析标准品,HPLC≥98%

人参皂苷 Rd Ginsenoside Rd 抑制 TNFα 诱导的 NF-κB 转录活性，IC50 为 12.05±0.82 μM。Ginsenoside Rd 抑制 COX-2 和 iNOS mRNA 的表达。Ginsenoside Rd 还抑制 Ca2+ 内流。Ginsenoside Rd 抑制CYP2D6，CYP1A2，CYP3A4 和 CYP2C9，IC50 分别为 58.0±4.5 μM，78.4±5.3 μM，81.7±2.6 μM 和 85.1±9.1 μM。

CAS No. :52705-93-8

商品编号	规格	价格	会员价	是否有货	数量
PC21349-20mg	20mg	¥455.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

*注意事项:下单时请联系销售核实产品价格及货期，避免后续产生不便，感谢支持!

加入购物车在线咨询收藏产品大包装询价

中文名称

人参皂苷Rd

中文别名

人参皂苷Rd;5-羟基奥美拉唑;WAKO072-03301人参皂苷Rd标准品;绞股蓝总皂甙;人参皂甙 Rd;人参皂甙 Rd Ginsenoside Rd;人参皂甙 Rd(标准品);人参皂苷 Rd(AS);人参皂苷Rd 对照品标准品;人参皂苷Rd 隐丹参酮丹参素钠冬凌草甲素;人参皂苷RD Ginsenoside RD Gypenoside VIII;人参皂苷Rd 标准品;人参皂苷Rd(标准品);人参皂苷Rd(人参皂甙RD);人参皂苷Rd,Ginsenoside-Rd,植物提取物,标准品,对照品;人参皂苷Rk1;人叁皂甙-Rd标准液;分析对照品;2-O-β-吡喃葡萄糖基-(3β,12β)-20-β-D-吡喃葡萄糖氧基-12-羟基达玛-24-烯-3-基-β-D-吡喃葡萄糖苷

英文名称

ginsenoside rd

英文别名

ginsenoside rd;GINSENOSIDE Rd(AS) PrintBack;GINSENOSIDE Rd(P) PrintBack;Gypenoside VIII;GINSENOOSIDERD;ginsenoside--Rd standard;Herba Gynostemmatis Pentaphylli;(3β,12β)-20-(β-D-Glucopyranosyloxy)-12-hydroxydammar-24-en-3-yl 2-O-β-D-glucopyranosyl-β-D-glucopyranoside;2-O-β-Glucopyranosyl-(3β,12β)-20-β-D-glucopyranosyloxy-12-hydroxydammar-24-en-3-yl-β-D-glucopyranoside;2-O-beta-D-Glucopyranosyl-(3beta,12beta)-20-(beta-D-glucopyranosyloxy)-12-hydroxydammara-24-en-3-yl-beta-D-glucopyranoside

Cas No.

52705-93-8

分子式

C₄₈H₈₂O₁₈

分子量

947.15

包装储存

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

生物活性

Ginsenoside Rd inhibits TNFα-induced NF-κB transcriptional activity with an IC₅₀ of 12.05±0.82 μM in HepG2 cells. Ginsenoside Rd inhibits expression of COX-2 and iNOS mRNA. Ginsenoside Rd also inhibits Ca influx. Ginsenoside Rd inhibits CYP2D6, CYP1A2, CYP3A4, and CYP2C9, with IC₅₀s of 58.0±4.5 μM, 78.4±5.3 μM, 81.7±2.6 μM, and 85.1±9.1 μM, respectively.

性状

Solid

IC50 & Target[1][2]

NF-κB

12.05 μM (IC₅₀, in HepG2 cells)

COX-2

L-type calcium channel

CYP2D6

58 μM (IC₅₀)

CYP1A2

78.4 μM (IC₅₀)

CYP3A4

81.7 μM (IC₅₀)

CYP2C9

85.1 μM (IC₅₀)

体外研究(In Vitro)

Ginsenoside Rd is one of the most abundant ingredients of Panax ginseng. Ginsenoside Rd significantly inhibits TNF-α-induced NF-κB transcriptional activity with an IC₅₀ of 12.05±0.82 in HepG2 cells. Ginsenoside Rd also inhibits expression of COX-2 and iNOS mRNA and iNOS promoter activity in a dose-dependent manner. To determine nontoxic concentrations, HepG2 cells are treated with various concentrations (0.1, 1, and 10 μM) of compounds (e.g., Ginsenoside Rd) and cell viability is measured using an MTS assay. No compounds are significantly cytotoxic at up to 10 μM, indicating that NF-κB inhibition is not due to cell toxicity. Ginsenoside Rd is one of the most abundant ingredients of Panax ginseng, protects the heart via multiple mechanisms including the inhibition of Ca influx. Ginsenoside Rd reduces I_Ca,L peak amplitude in a concentration-dependent manner (IC₅₀=32.4±7.1 μM). Ginsenoside Rd exhibits an inhibition against the activity of CYP2D6 in human liver microsomes with an IC₅₀ of 58.0±4.5 μM, a weak inhibition against the activity of CYP1A2, CYP3A4, and CYP2C9 in human liver microsomes with IC₅₀s of 78.4±5.3, 81.7±2.6, and 85.1±9.1, respectively, and an even weaker inhibition against the activity of CYP2A6 in human liver microsomes with an IC₅₀ value of more than 100 μM.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)

Ginsenosides Rd is a major compound isolated from Gynostemma pentaphyllum that holistically improves gut microenvironment and induces anti-polyposis in Apc mice. Six-weeks-old mice are subjected to Ginsenoside Rd treatment, before the appearance of the intestinal polyps. All the mice are monitored for food intake, water consumption, and weight changes. Throughout the experiment, no Rb3/ Ginsenoside Rd-associated weight loss in mice is observed. In addition, none of the treated mice show variations in food and water consumption. Whereas, the number and size of the polyps are effectively reduced by Ginsenoside Rd treatments.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

运输条件

Room temperature or refrigerated transportation.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

结构分类

来源

参考文献

[1]. Song SB, et al. Inhibition of TNF-α-mediated NF-κB Transcriptional Activity in HepG2 Cells by Dammarane-type Saponins from Panax ginseng Leaves. J Ginseng Res. 2012 Apr;36(2):146-52. [Information]

[2]. Liu Y, et al. Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes. Toxicol Sci. 2006 Jun;91(2):356-64. [Information]

[3]. Lu C, et al. Inhibition of L-type Ca current by ginsenoside Rd in rat ventricular myocytes. J Ginseng Res. 2015 Apr;39(2):169-77. [Information]

[4]. Huang G, et al. Ginsenosides Rb3 and Rd reduce polyps formation while reinstate the dysbiotic gut microbiota and the intestinal microenvironment in Apc mice. Sci Rep. 2017 Oct 2;7(1):12552. [Information]

溶解度数据

体外研究:

DMSO : 100 mg/mL (105.58 mM; Need ultrasonic)

配制储备溶液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.0558 mL	5.2790 mL	10.5580 mL
5 mM	0.2112 mL	1.0558 mL	2.1116 mL
10 mM	0.1056 mL	0.5279 mL	1.0558 mL

产品不同，其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液；配成溶液后，建议分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，建议在 6 个月内使用，-20°C 储存时，建议在 1 个月内使用。

体内研究:

建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 体外研究 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

建议依照次序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (2.64 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (2.64 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH?O 中，得到澄清透明的生理盐水溶液
2.

建议依照次序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (2.64 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (2.64 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

建议依照次序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (2.64 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (2.64 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

搜索质检报告(COA)

产品使用指南

Data Sheet

[1]. Song SB, et al. Inhibition of TNF-α-mediated NF-κB Transcriptional Activity in HepG2 Cells by Dammarane-type Saponins from Panax ginseng Leaves. J Ginseng Res. 2012 Apr;36(2):146-52. [Information]

[2]. Liu Y, et al. Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes. Toxicol Sci. 2006 Jun;91(2):356-64. [Information]

[3]. Lu C, et al. Inhibition of L-type Ca current by ginsenoside Rd in rat ventricular myocytes. J Ginseng Res. 2015 Apr;39(2):169-77. [Information]

[4]. Huang G, et al. Ginsenosides Rb3 and Rd reduce polyps formation while reinstate the dysbiotic gut microbiota and the intestinal microenvironment in Apc mice. Sci Rep. 2017 Oct 2;7(1):12552. [Information]

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

人参皂苷Rd

相关产品

The molarity calculator equation

The dilution calculator equation